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Abstract The tumor microenvironment has been widely exploited as an active participant in tumor 
progression. Extensive reports have defined the dual role of tumor-associated macrophages (TAMs) 
in tumor development. The protumoral effect exerted by the M2 phenotype has been correlated 
with a negative outcome in most solid tumors. The high infiltration of immune cells in the hypoxic 
cores of advanced solid tumors leads to a chain reaction of stimuli that enhances the expression of 
protumoral genes, thrives tumor malignancy, and leads to the emergence of drug resistance. Many 
studies have shown therapeutic targeting systems, solely to TAMs or tumor hypoxia, however, novel 
therapeutics that target both features are still warranted. In the present review, we discuss the role 
of hypoxia in tumor development and the clinical outcome of hypoxia-targeted therapeutics, such as 
hypoxia-inducible factor (HIF-1) inhibitors and hypoxia-activated prodrugs. Furthermore, we review 
the state-of-the-art of macrophage-based cancer therapy. We thoroughly discuss the development 
of novel therapeutics that simultaneously target TAMs and tumor hypoxia. Nano-based systems 
have been highlighted as interesting strategies for dual modality treatments, with somewhat 
improved tissue extravasation. Such approach could be seen as a promising strategy to overcome 
drug resistance and enhance the efficacy of chemotherapy in advanced solid and metastatic tumors, 
especially when exploiting cell-based nanotherapies. Finally, we provide an in-depth opinion on the 
importance of exploiting the tumor microenvironment in cancer therapy, and how  this could be 
translated to clinical practice. 
Keywords: 
Cancer hypoxia · Tumor-associated macrophages · Tumor microenvironment · Targeted cancer 
therapy · Nanomedicine 
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1. Introduction 
 Cancer is amongst the leading causes of mortality and morbidity worldwide. The latest 
statistics point to an estimated 14.1 million new cases and 8.2 million cancer-related deaths [1]. It 
has been characterized by an uncontrolled cell proliferation, which is often associated with vascular 
abnormalities and cell invasiveness. In the past few years, the hallmarks of cancer have been revised 
and an active participation has been assigned to the tumor microenvironment (Fig. 1) [2]. Studies 
have shown that cancer cells evolved to promote angiogenesis, metastasis and survival in response 
to several factors within the tumor microenvironment, such as pH, growth factors, oxygen levels and 
the presence of immune cells [3-5]. Tumor cells adaptation to the environment is considered 
essential to maintain their survival and growth. For instance, tumor cells grow under low levels of 
oxygen and nutrients, develop new blood vessels, a process called ‘de novo angiogenesis’ to 
compensate for the lack of oxygen and nutrients. These newly formed blood vessels contain 
discontinuous endothelium, which renders them leaky in nature. This vascular hyperpermeability, in 
combination with impaired lymphatic drainage, are known as enhanced permeation and retention 
effect (EPR) [6]. Surgery, radiotherapy, and classical chemotherapy are still the first options for many 
types of tumors [7]. However, the associated side effects and the emergence of multidrug resistance 
(MDR), have limited the clinical use of most common therapeutic compounds [8]. Therefore, there is 
an unmet need to develop novel approaches and therapeutics to target the tumor cell and its 
microenvironment. The heterogeneity and complexity of tumor microenvironme nt promote cancer 
survival and progression. Lately, research has focused on the involvement of tumor-associated 
macrophages (TAMs) in cancer progression. Studies have explored the link between the secretion of 
TAM chemoattractants by the tumor cells and the consequent upregulation of tumor-promoting 
genes by these immune cells, in response to the microenvironment stimuli [9, 10]. Additionally, 
hypoxia has been found as a critical factor for the survival of large tumor masses and therefore a key 
target for the development of targeted therapies [11]. Furthermore, high infiltration of TAMs are 
found in hypoxic tumor cores, promoting resistance to classical chemotherapeutics. This 
microenvironment may be used to develop sophisticated fine-tuned nano-based systems, capable of 
enhancing therapeutic extravasation into tumor hypoxic cores. Great efforts should be made to 
promote the rational design of delivery systems that could achieve high therapeutic efficacy by 
simultaneously targeting TAMs and hypoxia. 
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Fig 1. Main hallmarks of cancer. The cancer niche is a complex network of endothelial, stromal and malignant 
cells, comprised of evolutionary genomic features that enhance survival and thrive tumor cells to uncontrolled 
proliferation and metastasis.  This enriched tumor microenvironment supports a shifted metabolism in cells, 
which allows a quick preadaptation and survival under nutrient and oxygen d eprivation (hypoxia) which lead to 
therapeutic resistance.  
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2. Cancer Hypoxia  
Structural abnormalities in tumor vessels lead to reduced oxygen diffusion to tumor cells and 
eventually, necrotic cores. It has been fifty some years since Thomlinson and Gray first postulated 
the role of hypoxia in human tumors [12]. Hypoxia has an active role in oncogenesis and contributes 
to the overall survival of tumors. In normal tissues, oxygen levels are heterogeneous and 
physiological pO2 can range between 20 mmHg in the liver and brain to 70 mmHg in the kidney (3.1-
8.7 % O2). In contrast, a decrease to about 10-30 mmHg of pO2 is observed in tumors. Most 
importantly, 82% of all oxygen readings taken from solid tumors, present a 0.33 % O2 reading (as 
low as 2.5 mmHg) [13, 14]. The level of hypoxia within tumors increases during tumor progression. 
Chronic hypoxic cells have been described as prone to higher proliferation and survival. Aggressive 
phenotype with increased resistance to therapy has been associated with patients with highly 
hypoxic tumors, highlighting the clinical significance of hypoxia [15]. 
Hypoxia-inducible factors (HIFs), essentially HIF-1 have been linked to hypoxic tumor 
microenvironments. It is commonly overexpressed in solid and metastatic tumors including breast, 
prostate, colon, lung, pancreatic, head and neck cancer [16]. This molecule functions as a 
heterodimeric transcription factor composed of HIF-1α and HIF-1β, whose dimerization is regulated 
by an oxygen-dependent prolyl hydroxylase. When oxygen levels decrease, HIF-1α accumulates and 
translocates to the nucleus, where it forms the active transcription factor HIF-1 by binding to HIF-1β. 
This molecule regulates a plethora of genes in cancer biology and metabolism, controlling the 
proliferation rate, metastasis, and aggressiveness of cancer cells [17]. It also potentiates tumor cells 
resistance to radio and chemotherapy [18-20].  Although some controversy exists on using HIF-1 as 
an actual target for hypoxia, many novel therapies have been exploited, which will be discussed 
below, suggesting the relevance of hypoxia in cancer therapy. 
Several therapeutic agents, such as anti-angiogenesis (VEGF inhibitors) [14, 21, 22], tumor MAC 
depleting agents [23], and androgen deprivation therapy [19], have shown to induce tumor hypoxia. 
Most of these drugs work by shutting the blood supply to the tumor, reducing nutrient and oxygen 
delivery to the cancer cells, which results in tissue hypoxia. Photosensitizers are another class of 
cancer therapeutics, which consumes tumor oxygen upon light activation to produce reactive oxygen 
species (ROS), leaving lower oxygen levels in the tumor microenvironment [24, 25]. Drug-induced 
hypoxia has been considered indeed as a key factor that reduces the therapeutic efficacy of a wide 
range of anti-cancer treatments. However, recent studies have shown that careful selection of the 
combinatory treatment, as well as, their sequence, could convert hypoxia from a challenge into a 
potential therapeutic target. For instance, a recent study combining Topotecan (hypoxia-induced 
factor inhibitor) with Bevacizumab (antibody directed against VEGF) showed a synergistic antitumor 
activity in glioblastoma xenograft models [28]. A study by Mabjeesh et al, also identified a novel 
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antiangiogenic compound (2ME2), which induced downregulation of HIF-1 at a post-transcriptional 
level [21]. The data showed a significant antitumor effect, given HIF-1 induced down-regulation of 
VEGF. This rational provided evidence that dually targeting HIF-1 and other indirect pathways may 
be a robust strategy to overcome off-target therapy, and translate HIF-1 directed therapies to clinical 
development. Furthermore, a new interest has focused on designing multifunctional nanoparticles 
to deliver a combination of photosensitizers with hypoxia-activated prodrugs (HAPs) to tumor 
tissues, where induced hypoxia could activate HAPs, leading to a significant cell death and tumor 
growth inhibition [24, 25]. The latter approach will be discussed in more details in section 2.2. of this 
review. 
2.1. HIF-1 inhibitors 
The active role of hypoxia and HIF molecule has positioned them as novel therapeutic targets for 
cancer therapy [17, 26]. Classical approaches to overcome low oxygenation levels at the tumor site 
was carried out using hyperbaric chambers. Such intervention was proven to be unsuccessful in 
combination with radio and chemotherapy [14]. Therefore, new approaches have been introduced 
to target tumor hypoxia and small molecules that specifically target HIF-1, a master transcriptional 
factor that regulates cancer progression and development, are highly attractive. Existing therapeutic 
options, consider HIF-1 as a new gold standard target to treat cancer. Several small inhibitors have 
been developed and can inhibit HIF-1’s activity by promoting HIF-1 protein degradation, or by 
blocking at least one of the following pathways: 1) HIF-1 mRNA expression; 2) HIF-1 protein 
translation; 3) HIF-1 DNA binding and 4) HIF-1 transcriptional activity [27, 28]. The demanding role 
and complex network underlying the HIF molecule indirect inhibitors have been thoroughly 
reviewed [29]. These include molecules that target upstream or cross-talked pathways with the HIF 
target (e.g. inhibitors of VEGF, mTOR, epithelial growth factor receptor (EGFR), topoisomerase I and 
II, PI3/ AKT/MAPK pathways). Despite the discovery and development of several therapies targeting 
HIF-1 or HIF-1 pathways, only a few have progressed into clinical development (Table 1). There have 
been no approved drugs that directly inhibit HIF-1, and many small molecule inhibitors have shown a 
high rate of late-stage clinical failure. This is attributed to the high redundancy and complexity of the 
tumor microenvironment.  Furthermore, the desired effects of indirect inhibitors may be difficult to 
separate, as many different signaling pathways are linked to HIF-1 induced tumorigenesis, leading to 
the existence of off-target effects that are likely to be less predictable [30]. However, as mentioned 
above, recent studies have shown that dually targeting HIF-1 and other indirect pathways may be a 
strong strategy to overcome off-target therapy and translate HIF-1 directed therapies to clinical 
development [21, 22, 31]. 
Although there is a much better understanding of the pathway today than in the early 1990s 
when HIF-1 was discovered, its dual role in promoting cell survival and inducing apoptosis has 
caused controversy among researchers as to whether it should be considered as a therapeutic target 
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[32].  Nonetheless, selective gene therapy can be achieved by designing therapeutic genes, which 
are controlled by response to binding of HIF-1 to HREs (hypoxia responsive elements). Shibata et al 
(2
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Table 1. Most promising HIF-1 inhibitors in preclinical and clinical trials.  
Drug Method of action Stage Chemical class Cancer type Limitations Main observations/conclusions Reference(s) 
17-AAG 
(tanespimycin) 
and 17-DMAG 
(alvespimycin) 
Bind to chaperone protein 
Hsp90, inducing 
proteosome degradation of 
HIF-1α 
Phase I  
and II  
Second 
generation 
benzoquinone 
ansamycin 
antibiotics  
Prostate, 
hepatic, 
colon, 
ovarian, 
breast and 
gl ioma  
Off target 
effects , poor 
bioavai labi l i ty 
and solubi l i ty 
 
Fi rs t generation: ga ldanamycin - blocked HIF-1α protein 
expression in both serum and serum free normaxic and 
hypoxic conditions . Fa i led to enter cl inic due to poor 
pharmacologica l  properties  and hepatoxici ty in animal  
models ; 
17-AAG was  the first-in-class Hsp90 inhibitor to enter Phase 
I  tria ls. Showed poor results in Phase II  tria ls : 1) effect on 
RAF kinase expression were short-l ived, and no objective 
anti -melanoma responses were seen; 2) At the dose and 
schedule used in this trial, 17-AAG did not achieve objective 
response in the treatment of clear cell or papillary renal cell  
carcinoma patients . 
17-DMAG, an ora lly available agent, has shown promise in 
the cl inic, with success  in Phase I  tria ls . 
 
[22, 27, 31, 33-
35] 
YC-1 
Inhibi tion of HIF-1α 
accumulation, poss ibly 
through an independent 
ubiquitin/proteosome 
pathway 
 
Preclinical Benzyl indazole  
Multiple 
tumors  
Unknown 
mechanism of 
action 
 
Interferes with mitogen pathways  and thus  affecting the 
trans lational  process  of HIF-1α; 
Down-regulates  HIF-1α mRNA trans lation; 
Fi rs t s tudy to show hypoxia  and mitogen-dependent 
inhibi tion of both HIF-1α and HIF-1β accumulation. 
 
[36] 
EZN-2968 
Ol igonucleotide targeting 
HIF-1 antisense mRNA 
Phase I  
Anti -sense 
ol igonucleotide  
Metastatic 
l iver cancer 
s iRNA 
del ivery 
 
In vitro s tudies in prostate cancer and glioblastoma showed 
[37-40] 
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a potent selective and durable antagonism (IC50 1-5nM), 
under hypoxia  and normaxia; 
VEGF levels  are reduced, a longs ide tumor reduction in 
xenograft models ; 
The activi ty of EZN-2698 in clinical trials at the doses tested 
was  minimal  and the s tudy was  ha l ted. 
 
AFP464 
HIF-1 mRNA 
interference 
Phase I  Aminoﬂavone  
Advanced 
metastatic 
sol id tumors  
Mechanism 
of action i s  
unknown 
 
 
Modulates mRNA expression of HIF-1α (full mechanism stil l  
not elucidated) and dimerizes  with HIF-1β; 
Acts  as  a  l igand for the aryl -hydrocarbon receptor, but 
inhibition of HIF-1 accumulation is  independent on the 
receptor, a l though some data  indicates  otherwise; 
Cl inical results have been observed for breast, renal  and 
ovarian cancer, with maximum tolerabi l i ty assessed. 
[37, 41] 
Topotecan 
 
Inhibits HIF-1 translation by 
targeting topoisomerase I  
Pi lot 
s tudy 
Fluorine-19-
Fluoroded 
 
Sol id 
metastatic 
tumors  
Short 
ha l f-l i fe 
 
FDA approved, as a  second line of therapy for patients with 
smal l  cel l  lung or ovarian cancer; 
Inhibits HIF-1 translation in a  DNA damage independent 
mechanism, but acts  as  a  poison for topois omerase I; 
Results in a mouse xenograft model showed inhibi tion of 
HIF-1 express ion, angiogenes is  and tumor growth. An 
ongoing pi lot s tudy i s  in order. 
 
[22, 42, 43] 
EZN-2208 
Inhibits HIF-1 translation by 
targeting topoisomerase I  
Phase I  & 
II  
Pegylated form of 
Irinotecon 
(camptothecin) 
Metastatic 
colorecta l  
cancer 
Off-target 
effects  
 
Showed remarkable antitumor activity in pre -clinica l  tria ls  
for solid tumors  and lymphoma, due to high solubi l i ty, 
accumulation and ci rculation time; 
In combination therapy trials  with cetuximab, both drugs  
[44, 45] 
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were well tolerated, but no differences were obtained in the 
overa ll survival and progression, when comparing mono and 
combined therapy. 
 
Digoxin Inhibits HIF-1α trans lation Phase II  Cardiac glycoside 
Operable 
breast cancer 
Narrow 
therapeutic 
window 
 
 
Digoxin and other cardiac glycosides blocked express ion of 
HIF-1α even in the presence of the PHD -VDL pathway; 
Therapeutic action occurs  even under normaxia; 
A 73% inhibi tion of HIF-1α trans lation occurs  after 
treatment with Digoxin, whi le only 17% of overa l l  
accumulate protein i s  degraded; 
Blockage of expression occurs for P493 and PC3 cel l s , both 
in vitro and in vivo. 
 
[46] 
PX-478 
Blocks deubiquitination and 
reduces  transcription/ 
trans lation 
Phase I  
phenyl propionic 
acid N-oxide 
dihydrochloride  
Advanced 
sol id tumors  
and 
lymphoma  
Off-target 
effects  
 
Reduced tumor volume by 87% and mediastinal metastas is  
contributing to overall prolonged survival of NSCLC models ; 
Highly active against orthotopic models  of human lung 
cancer; 
The drug was also observed to decrease overall total protein 
synthesis , with a  more pronounced effect in hypoxia  in 
prostate cancer cel l s . 
 
[47, 48] 
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proved this concept through the development of vectors containing a bacterial nitroreductase gene, with a 
responsive domain to VEGF [49]. This system was used to selectively activate an anticancer prodrug 
(CB1954). In a similar approach, the HRE vector was for human flavoprotein cytochrome P450 reductase, 
which was also used to selectively activate RSU1069 prodrug [50]. Both studies showed increased 
cytotoxicity in hypoxia, compared to normaxia. 
Hypoxia-driven triple suicide genes have also been explored to increase the cytotoxicity of ganciclovir 
(GCV) and 5-fluorocytosine (5-FC) both in vitro and in vivo [51]. Additionally, antisense or small interfering 
RNA (siRNA) plasmids injected in hypoxic tumors has shown to eradicate EL-4 thymic lymphoma in 
combination with angiostatin [52]. Although these systems have shown an interesting outcome, off-target 
effects are still an issue, if injected intravenously. The use of drug carriers could further improve the efficacy 
and safety of gene delivery to the hypoxic tumor microenvironment.     
2.2. Hypoxia-activated prodrugs 
The concept of bio-reductive prodrugs (also known as hypoxia-activated prodrugs) has arisen, and the 
use of drugs that are non-toxic until they are reduced under low oxygen levels has opened the door to 
specific systemic treatments of solid and metastatic tumors [53]. Hypoxia-activated prodrugs are defined as 
cytotoxins that are metabolized by various endogenous reducing enzymes (oxireductases such as NAD(P)H, 
cytochrome P450) and quinone oxidoreductase (NQO1 in a one-electron or two-electron catalysis). The one 
step electron reduction is a selective process, as it composes a reversible step that generates a prodrug free 
radical that can easily back-oxidized to its original compound if oxygen is present, conferring specificity to 
highly hypoxic regions. Contrary to this, the two-electron reduction fails to produce an oxygen sensitive 
intermediate, being highly toxic, even for tissues in normaxia. The choice of which reduction occurs depends 
on the structure of the compound itself and the differential expression of reducing enzymes in tissues [20, 
54]. The different classes of hypoxia-activated prodrugs are: (nitro (hetero) cyclic compounds; aromatic N-
oxides; aliphatic N-oxides; quinones and metal complexes. These drugs are thoroughly summarized in Table 
2, with the indication of their overall success in clinical trials. Although the values of these prodrugs are 
highly dependent on their relative metabolism and penetration, many have progressed significantly and 
showed promising applications as selective hypoxic cytotoxins [53].  
Tirapazamine (TPZ) is the most clinically advanced hypoxia- activated prodrug [45]. Early clinical studies 
for non-small cell lung cancer (NSCLC), head and neck-cancer, metastatic melanoma (Phase I and II) and 
other solid tumors, showed enhanced tumor inhibition for this agent [55, 56]. This was achieved by co-
administering TPZ with radiosensitizing and platinum agents. Furthermore, a dose-defining study of TPZ 
combined with embolization in liver cancer is now recruiting [57] . However, unexpectedly, a recent 
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randomized clinical trial combining radiation and cisplatin, with TPZ, for cervical cancer (Phase III) [58], 
showed that the combined 
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Table 2.  Bioreductive prodrugs for hypoxia. 
Prodrug 
Method of 
action 
Stage Chemical class Cancer type Limitations Main observations/conclusions Reference(s) 
Tirapazamine 
Complex DNA 
damage 
Phase II I  
Aromatic 
N-oxide 
Head and neck 
(phase I and II) 
and cervix 
(Phase II I) 
low drug 
penetration and 
accumulation in 
tumor tissues  
 
Potentiates antitumor effects  after radiation sens i tization; 
Phase I  and II  clinical trials, showed overall promising effects of 
TPZ in combination with radiation and cisplatin; 
CATAPULT 1 cl inica l  tria l  for NSCLC showed an increase to 
33.9% surviva l  rate over 1 year 
Recent Phase II randomized cl inica l  tria ls  for head and neck 
cancer, showed no overall significant effect on response rate 
and surviva l ; 
Review of populations  used may be in order for correct 
assessment of the activi ty of the drug. 
[55, 58-60] 
SN30000 
(CEN-209) 
Complex DNA 
damage 
Preclinical 
Aromatic N-oxide 
(analogue of TPZ) 
Multiple 
tumors  
Scarce l i terature 
reports  
 
Has  undergone extensive optimization to overcome low drug 
penetration and accumulation; 
Scheduled to enter Phase I  cl inica l  tria ls . 
[61] 
Apaziquone 
(E09) 
DNA 
interstrand 
cross l inking 
Phase II I  Quinone Bladder 
Poor 
pharmacokinetic 
properties ; 
 
Results considering recurrence rates showed encouraging data  
(only 34.7 recurrence over 12 months  and 48% after 18 
months); 
No activi ty was  seen against a  wide range of tumors  in 
subsequent phase II trials, probably due to the drug limitations; 
A promising outcome was seen, after adminis tration of the 
drug directly into the urinary bladder. 
[62-64] 
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Evofosfamide 
(TH-302) 
DNA 
interstrand 
cross l inking 
Phase 
II/II I  
Ni troimidazoles  
Multiple 
tumors  
Optimization of 
therapeutic 
regimen of 
combined therapy. 
One drug may 
compromise the 
action of another 
 
Shows promise in terms of balance between s tabi l i ty and the 
reduction/oxidation equi l ibrium; 
Precl inical studies indicated a  potent broad activi ty in various  
ectopic, orthotopic and metastatic models, for both mono and 
combined therapy; 
Phase I  trials indicated good tolerance of the drug and parti a l  
responses  in patients  with metastatic lung cancer and 
melanoma; 
Phase II  tria ls  showed efficacy in combined therapy with 
gemcitabine and doxorubicin, under normoxia and hypoxia and 
ongoing phase II I  cl inica l  tria ls  are in order. 
[65-68] 
PR-104 
DNA 
interstrand 
cross l inking 
Phase II  
Ni trobenzamine 
mustard 
Leukaemia  
Activation by 
aerobic reductases  
reduces  hypoxia  
selectivi ty 
 
Showed 10  to 100 fold increased activi ty in hypoxia , in vi tro, 
for a  broad range of cel l  l ines , as  wel l  as  a  s ingle agent 
efficiency in 6 of 8 xenograft models  tested; 
Additive effect in combination therapy was observed, for both 
in vi tro and human panels. Potentiation of drug may be due to 
a  bystander effect caused by activation in oxygen present 
environments  and hypoxia . 
[69-73] 
Banoxantrone 
(AQ4N) 
DNA 
interca lator 
and 
topoisomerase 
II  inhibi tion 
Recent 
phase I/II  
Al iphatic N-oxide 
Multiple 
tumors  
Lack of 
experimental  data  
in patients , results  
may not be ful ly 
trans lated into 
therapeutics  
 
Measurable decreases  in hypoxic cel l s  was  observed and 
precl inical activity indicated accumulation of the drug in 24/30 
tumor tissue samples ; 
Radiation conditions , cisplatin and other combinatoria l  
chemotherapy regimens have shown to have effect with this  
drug; 
AQ4 the active metabolite, after reduction, co-loca l i zes  with 
[37, 74, 75] 
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Glut-1 and hypoxic regions . 
SN-24771 
Reduction of 
metal centers  
[Co (II I) to Co 
(II], 
Pre-
cl inica l  
Metal  complexes  
Multiple 
tumors  
No development for 
cl inica l  use 
 
This  compound showed moderate activity in vi tro, but failed to 
reproduce activi ty in in vivo hypoxia ; 
It forms  an unstable compound that releases  i ts  mustard 
l igand, destabi l i zing DNA; 
Other selective metal  complexes  have been reported, but 
improvement regarding this  class  of bioreductive drug i s  
needed. 
[27, 53] 
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treatment was not superior to cisplatin alone, since no change in the overall survival rate was 
observed. Although these results seem disappointing, one must take into account the small 
population size for this particular trial, and that the patients may constitute a non-selective hypoxia 
sub-population [60]. Therefore, we believe that it is essential to overlook apparent clinical failure 
and understand the overall limitations of these pro-drugs. This can be achieved by using in vitro 
systems that can accurately validate the therapeutic efficacy of these drugs. Furthermore, 
translation to clinical scenarios should be based on selecting hypoxia sub-populations. Evofosfamide 
(TH-302) is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-
isophosphoramide mustard under hypoxic conditions [66]. Phase I/II clinical trials have shown 
promising results for the drug as both a single agent and in combinatorial treatments with 
gemcitabine and nab-paclitaxel for pancreatic cancer [67, 68, 76]. A phase I/II Open-label Study of 
TH-302 and dexamethasone in subjects with relapsed/refractory multiple myeloma is now recruiting 
[77]. Phase II placebo-controlled study of TH-302 in combination with Pemetrexed in patients with 
non-squamous non-small cell lung cancer has started (NSCLC) [78]. PR-104 is a water soluble 
phosphate ester that has shown rapid hydrolysis in vivo with promising preclinical outcomes [79]. 
PR-104 is currently in Phase II trial for relapsed or refractory acute myeloid leukemia [71]. 
Although several hypoxia-activated prodrugs have progressed into clinical trials, their poor 
extravascular space penetration, short blood half-life, instability and poor balance between the 
reduction/oxidation equilibrium, have limited their accumulation in the target tissues [53]. A 
solution to overcome these limitations may underlie the development of novel carriers to deliver 
these drugs. Therefore, improving their cellular uptake, specificity, tissue penetration, 
pharmacokinetics and dynamics [80, 81]. From a clinical point of view, the standardization of 
treatment, dynamic interplay between hypoxia and other molecular determinants, as well as the 
poor definition of patient subgroups for hypoxia-targeted treatment, has caused limited positive 
clinical outcomes and warrants further evaluation [16, 82]. In support of these findings, recent 
studies have utilised nanocarriers to improve HAPs poor in vivo distribution, and to offer a 
combinatory treatment with photosensitizers. TPZ is well known for its moderate to severe hypoxia 
activation, but other HAPs seem to have a narrow window of action. The use of photodynamic 
therapy (PDT) could create a more selective hypoxia environment through photosensitization, with 
increased synergism with HAPs.  Shi et al and his co-workers presented an interesting piece of work 
where they validated that photosensitizers can indeed produce a strong enough hypoxia 
environment that can potentiate the action of HAPs [25]. In this paper, double layered silica-shell 
nanoparticles were developed, which were capable of co-delivering a photosensitizer (UC/PS) and 
TPZ. The drug-loaded nanoparticles (TPZ-UC/PS) showed excellent biocompatibility and sufficient 
oxygen depletion by the photosensitizer, resulting in a significant reduction in cell viability. 
Furthermore, they showed a remarkable reduction in tumor volume after near-infrared irradiation 
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(NIR). These combinatorial synergistic systems could offer a potential treatment for patients with 
large deep-seated tumors. In the same line of work, a mesoporous silica-based theranostic platform 
was also developed for synergistic PDT and hypoxia cancer therapy [24]. CD44- targeted system was 
comprised of a layer-by-layer silica nanoparticles that were used as a drug reservoir for TPZ, with an 
assembled supramolecular photosensitizer (TPPS4), coordinated with the paramagnetic agent 
gadolinium-III for tumor-targeted diagnosis and treatment. Interestingly, PDT-induced apoptosis was 
confirmed by enhanced ROS production and the system showed a remarkable synergistic effect 
under 21% oxygen conditions, where the most significant reduction in tumor volumes was observed 
in mice co-treated with PDT and TPZ nanoparticles. These two studies confirmed that PDT could be 
used as a successful approach to activate HAPs, and to induce a synergistic effect in vivo models. 
3. Tumor-associated macrophages (TAMs) 
3.1. Macrophages in the tumor microenvironment 
The presence of dendritic cells, fibroblasts, endothelial ce lls, monocytes and macrophages in the 
tumor microenvironment has been repeatedly linked to tumor progression [83]. The high infiltration 
of the immune cells in the tumor microenvironment, essentially in the hypoxic cores of tumors, has 
been correlated with a negative clinical outcome concerning patient’s survival.  
Monocytes are the primary moderate phagocytic cell type that contain primary lysosomes and 
have an overall pro-inflammatory effect. These cells circulate for about 1 to 3 days and afterward 
move to tissues where they mature into more active phagocytic cells, the macrophages (MACs) [84]. 
These cells are native residents of organs such as the liver, lung, spleen, lymphatic nodes. They have 
an important immunosurveillance role, mainly responsible for tissue repair, wound healing and 
defense against pathogens, including tumor cells [85]. However, a differential MAC programming in 
cancer progression has been elucidated, and much needs to be taken into account when describing 
the primary role of these cells in the tumor microenvironments [86]. MACs are particularly abundant 
and present at all stages of tumor progression. Their role in the tumor environment has reached a 
concept of ‘friend or foe’, recognizing that a well - functioned immune system should destroy tumor 
cells [87]. Nonetheless, many cancer cells escape the tight immune surveillance and redirect immune 
cells to their advantage. This escape is due to the development of deficiencies in antigen processing 
and presentation in several MAC pathways, and the consequent production of immune suppressive 
cytokines [88]. Tumor cells are known to secrete different cytokines, which control the balance 
between pro-inflammatory and anti-inflammatory components that in turn are responsible for this 
dual shift in MAC genomics and proteomics. Chemotactic cytokines, such as CXCL1, CXCL8, CXCL12, 
CXCL13, CCL5, are used to attract circulating monocytes to the tumor microenvironment [89-91]. 
These residing monocytes can then differentiate into MACs and initiate an inflammatory imbalance 
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that causes a vicious cycle in which MACs initially control tumor development, but once established, 
are educated to become protumoral [23, 92].  
3.2. Differential polarization and the relevance of the M2 protumoral effect 
Two different polarization status have been reported amongst the MACs population [93]. The M1 
phenotype (classically activated form) is responsible for host defense. When activated by Interferon 
gamma (IFN- γ) and/or lipopolysaccharides (LPS), M1 MACs produce large amounts of pro-
inflammatory cytokines, such as oxygen species (e.g. nitric oxide), high levels of MHC (Major 
Histocompatibility Complex) molecules, interleukin 12 (IL-12) and low levels of IL-10. These 
characteristics make them potent killers of pathogens and tumor cells. On the other hand, the M2 
subtype (alternatively activated form) responds to stimulus from IL-4/IL-13, IL-10, Toll-like receptors 
(TLR), glucocorticoids, allowing the development of MACs involved in tissue remodeling,  
angiogenesis, immune-regulation (M2b or M2c) and tumor development (M2a). These cells produce 
high amounts of IL-10, tumor necrosis factor (TNFα) and arginase-1. They over-express scavenger 
receptors, mannose receptors and exhibit anti-inflammatory activity [94, 95].  
The definition of M1 and M2 is not a ‘black and white’ concept.  M2 type MACs are not simply 
defined by their location, but also by the stimuli they receive in the specific environments, in which 
they reside. Although these extreme forms of polarization are seductive, it seems that the multiple 
tumor-associated macrophages (TAMs) phenotype is dependent on the stimuli received in the 
complex network of signaling in the tumor microenvironment, as well as the tumor itself [92]. TAMs 
have been defined to closely resemble the M2 phenotype, and to constitute up to 80% of the tumor 
mass [93]. They are highly accumulated in poorly vascularized, hypoxic and necrotic areas, 
contributing to a poor prognosis and exerting a protumoral effect in many types of solid tumors [96, 
97]. 
Over forty years ago, a study by Fidler in 1974 [98], demonstrated that intravenous injection of 
specifically activated MACs (M1 phenotype) inhibited lung tumor metastasis. On the other h and, 
Gorelik et al [99] showed that injecting M2 MACs intravenously in mice increased the development 
of lung cancer nodules. In the last two decades, studies have shown that co-culturing tumor cells in 
vitro with M2 MACs, even in the absence of a direct contact, increased tumor angiogenesis, 
progression and invasiveness [100-103]. These results highlight the different roles that polarized 
MACs play in cancer progression. 
3.3. M2 MACs as promising therapeutic targets for cancer  
Several studies have shown that MACs play a fundamental role in tumor development, and, 
therefore, remain a respectable therapeutic target in cancer therapy [104]. M2 MACs overexpress 
different types of receptors, which makes them excellent targets for drug delivery. A summary of the 
different targeted delivery systems to these MACs is shown in Table 3.
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Table 3. Successful targeting approaches for TAMs. 
Targeting 
receptor 
Targeting ligand 
Therapeuti c 
agent 
De l i very sys tem Tumor mode l  Outcomes  Ref erence( s )  
Mannose  
( CD206+ human, 
CD205+ murine)  
Glucomannan Alendronate 
Conjugated 
polysaccharide 
vehicle 
Mouse macrophage cel l  l ine Raw 
264.7, mouse sarcoma cel l s , 
human umbilical vein endothel ia l  
cel ls and human lung carcinoma 
A549 cel l  l ine; 
Murine sarcoma S180 in vivo 
model  
 
Both ALN and ALN-BSP (100 mM) induced RAW 264.7 
apoptos is ; 
Fluorescent images  and flow cytometry analys is  
suggested that ALN-BSP was preferentia l ly taken up by 
Raw 264.7 macrophages  (33.1%), in comparison to 
HUVECs  (11.2%) and A549 (2.36%); 
ALN-BSP was found to inhibit angiogenes is  (decreased 
the level of VEGF by 83.9%) and e xpress ion of MMP (by 
65.3%). 
[105] 
Anti -MMR 
speci fic 
nanobodies  
N/A Nanobody based 
C57BL/6 MMR-deficient, CCR2-
deficient, and MMTV-PyMT mice; 
Ba lb/c mammary adenocarcinoma 
models  
 
In vivo injection of 99mTc-labeled α-MMR Nb tumor 
bearing mice confi rmed i ts  speci fici ty to TAM’s ; 
Co-sta ining for the nanobody and hypoxic showed that α-
MMR Nbs  can target hypoxic tumor regions  in vivo. 
[106] 
Alkyne 
functional ized 
mannose 
s iRNA 
Polymeric micel les  
(pH sens i tive 
hemolys is ) 
Murine BMDM’s ; 
Human macrophages  (THP-1); 
Breast cancer cell lines  (MDA-MB-
231 and MDA-MB-468) 
 
The tri -polymer efficiently complexed s iRNA and 
protected the genetic cargo. 
Macrophages presented a  26-fold increase uptake of 
selected micel les , comparative to tumor cel l s ; 
Flow cytometry results showed that mannose targeting 
s ignificantly increased the rate of delivery of s iRNA into 
macrophages and generated a robust knockdown of the 
model  gene. 
[107] 
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O-stearoyl  
mannose 
N/A 
PEG-sheddable 
mannose modified 
PLGA nanoparticles  
J774A.1 murine macrophages ; 
B16-mouse melanoma tumors  in 
C57BL/6 mice 
 
Pegylation of M-NP s ignificantly decreased the cel lular 
uptake by 75%; 
After injection of the nanoparticles  into C57BL/6 mice 
the PEG shielding was important to minimize uptake by 
off-targets ; 
Injection of modified and unmodified particles  in mice, 
showed higher tumor accumulation, as  PEG shielding 
enhanced ci rculation time. Acid- sensitive PEG shedding, 
a l lowed for a  specific and localized binding and efficient 
uptake by M2 type MACs. 
[108] 
CSF -1R 
Anti -CSF-1R 
(RG7155) 
N/A N/A 
TAMs in vitro, in in vivo animal  
models  (male cynomolgus  
monkeys, Female C57BL/6N mice) 
and in RG7155-treated Dt-GCT 
patients  
 
G7155 potently inhibi ted the viabi l i ty of CSF-1-
di fferentiated macrophages  with an IC50 of 0.3 nM; 
RG7155 mediated rapid el imination of a l ternatively 
activated MACs  (CD14+CD16+), but not of classica l  MACs  
(CD14+CD16−), in cynomolgus  monkeys ; 
Cl inical activity correlated with a  significant reduction of 
CD68+/CD163+ macrophages  and of CSF-1R+ cel l s  in 
matching tumor biops ies  and the dramatic TAM 
reduction was  independent of the degree of basa l  
macrophage infi l trate. 
[109] 
Legumain Legumain N/A 
DNA construct 
encoding legumain 
Murine macrophage cell line RAW 
264.7, murine 4T1 breast 
carcinoma cells and female BALB/c 
and C57BL/6 mice  
 
Lung metastasis’s weights were determined at 24 days or 
30 days  after. Differences between the 2 control  groups  
(PBS and/or empty vector) and the treatment group were 
s tatis tica l ly s igni ficant; **P < 0.005. 
It was  shown that, T cel l  response abrogated M2 type 
macrophages after application of the legumain -based 
[110] 
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DNA vaccine, which in turn effectively inhibi ted 
spontaneous  4T1 breast cancer metastases . 
In murine models of metastatic breast colon, and non –
small cell lung cancers, 75% of vaccinated mice survived 
lethal tumor cell challenges  and 62% were completely 
free of metastas is . 
Macrophage  
galactose - type  
lectin ( Mg1)  
Galactose 
CpG ODN 
Anti -IL-10 ODN 
and IL-10RA 
ODN 
Cationic dextran 
based nano-
complex 
Hepa-1-6 mouse hepatoma cel l  
l ine and female ICR mice a s  
a l lograft model  for l iver cancer 
 
Compared to control, FITC-ODN monitoring confi rmed 
efficient transfection of and blockage of Mg1 in vivo, 
whi le the pH sensitive moiety conferred control led and 
accurate release of the ODN from the complexes ; 
The nano-complex reversed TAM phenotype by 
decreasing M2-specific genes: Arg-1, Ym1, Mg1, Mg2 and 
IL-10. Additionally, this system showed enhanced anti -
tumor activi ty in an a l lograft model , as  mean tumor 
weights were reduced and histological analys is  of l iver, 
showed large necrotic areas . 
[111] 
IL-4Rα  
Peptide 
(CRKRLDRNC) 
N/A N/A 
CHO-K1 cel l  l ine and C567BL/6 
male mice 
 
The peptide did not home to other organs  and co -
loca l i zation of the peptide with macrophages  was  
observed; 
The peptide bound s trongly to CHO-K1 cel l s  
overexpressing IL-4Rα, compared to control. CRKRLDRNC 
bound both human and murine cells , presenting cross -
reactivi ty of species . 
[112] 
Anti -IL4 
aptamer 
N/A N/A 
4T1 and MSC2 cel l  l ines  
BALB/C mice 
 
FACS analysis showed that the aptamer preferentia l ly 
bound its ligand in vivo, with enhanced targeting of TAMs 
in tumor bearing mice; the aptamer recognized and 
[113] 
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bound both murine and human MACs; 
It may a lso trigger biological activi ty, possibly through a  
pro-apoptotic activi ty on TAMs, as  tumor growth was  
inhibi ted in mice treated with the aptamer and a  
dramatic decrease in secondary metastas is  was  a lso 
observed. 
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The principal mechanisms of MAC-based anticancer therapy rely on 1) inhibiting monocyte 
maturation in resident tumors; 2) depleting M2 type MACs; and 3) shifting polarization to an M1 
phenotype with the pro-inflammatory response.  
Therapeutic agents have been developed to target TAMs. For instance, trabectedin is an anticancer 
drug, licensed to treat advanced soft tissue sarcoma and recurrent ovarian cancer. It works by 
inhibiting macrophage colony-stimulating factor (M-CSF)-driven differentiation of monocytes into 
MACs, and blocking the production of CCL2, IL-6, and VEGF, causing a subsequent inhibition of  
tumor progression [114-117]. Prednisolone is a second class of drug (glucocorticoid) that inhibits 
monocyte differentiation. Systemic administration of prednisolone phosphate (PLP) encapsulated in 
long-circulating liposomes (LCL-PLP) significantly reduced M2 MAC levels in the tumor tissue, 
decreased the production of chemoattractants involved in the infiltration of monocytes into tumor 
microenvironment, and lowered the production of angiogenic factors by M2 MACs [118-120]. 
Metalloproteinase-9 (MMP-9) is a protein that is expressed by M2 MACs, which in turn triggers the 
release of VEGF, a factor important in the angiogenesis of tumors. Inhibiting tumor 
metalloproteinase activity, and diminishing the association of VEGF with its tyrosine kinase receptors 
on proliferating endothelial cells, may be an effective strategy to inhibit tumor growth.  Clodronate, 
a bisphosphonate drug that blocks the activity of MMP-9 in TAMs. A liposome-based carriers 
containing clodronate (LIP-CLOD) selectively targeted MMP-9 following phagocytosis and 
intracellular drug release. MACs phagocytosed the LIP-CLO, which were subsequently degraded by 
the lysosomal phospholipases releasing the clodronate into the cell and inducing apoptosis, and 
reduced blood vessels formation [121].  
The third mechanism in MAC-based anticancer therapy relies on shifting M2 polarization to M1 
MACs [122]. TAMs express primarily M2-like phenotype, but can polarize to a classical M1-like 
phenotype, due to their high plasticity. For M1 polarization to occur two specific pathways have to 
be targeted, nuclear factor-κB (NF-κB) and the signaling transducer and activator of transcription 
(STAT) pathway. Toll-like receptors (TLR) are also expressed on MACs and is considered essential for 
the activation of NF- κB pathway, causing a reverse in MAC phenotype [88]. TLR agonists and 
inducers of NF- κB pathway have been exploited, causing a significant decrease in tumor growth 
[123]. Murphy et al demonstrated that Azitromycin-treated J447 mouse MAC cells, produced lower 
levels of pro-inflammatory cytokines and higher levels of anti-inflammatory cytokines[124]. This 
clearly demonstrated the capacity of this antibiotic to shift the M1 polarization to M2. This study 
contributed to a better understanding of MAC function and polarizability in early inflammation. 
However, further studies to evaluate the clinical application, are still needed.  
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Gene therapy has also been explored to re-educate TAMs at tumor tissues. Adenoviral 
transduced MACs with IL-12 were used to treat orthotopic 178-2 BMA mouse prostate cancer 
model. The systemic administration of over-expressing IL-12 M1 MACs significantly reduced the 
growth of primary tumor and its metastasis in mice [97, 125]. Lately, nano-carriers containing 
retinoic acid succeed in reverting M2 phenotype into M1. Flow cytometry and fluorescent 
microscopy analysis demonstrated that these nanocarriers were efficiently taken up by MACs, 
following systemic administration and remained engulfed in TAMs for 7 days [126].  Another study 
by Lobenberg group reported the capacity of doxorubicin-loaded nanoparticles to activate MACs 
(shifting naïve MACs to a M1 phenotype) after phagocytosis, which led to a significant cell death in 
cancer cells [127]. 
4. The link between hypoxia and TAMs: the promising role of targeted drug delivery 
systems 
Evidence has connected tumor aggressiveness and poor patient survival to the hypoxic regions of 
tumors. TAMs infiltrate the hypoxic perinecrotic areas of the tumors, due to the increased number 
of cellular debris in those regions. Therefore, promote immune  suppression, angiogenesis, 
lymphogenesis and matrix remodelling [9, 10]. Such correlation has been observed in patients 
diagnosed with breast, prostate, ovarian and cervical cancer [128, 129]. TAMs have been able to 
modulate the transcription factor HIF-1, several survival pathways, such as phosphatidylinositol 3-
kinase (PI3K) or mitogen-activated protein kinase (MAPK) pathway, as well as regulate tumor 
angiogenesis and metastasis [19, 20].  Recent reports have suggested that HIF-1 is overexpressed by 
TAMs, thus completing the vicious cycle that promotes cancer survival, progression and resistance to 
therapy [15] (Fig. 2). HIF-1 transcription factor not only modulates the expression of cancer-related 
genes in TAMs, but also provokes a metabolic shift in these immune cells, thriving the tumor 
development under nutrient and oxygen deprivation [130].  
Individual and combinatorial systems exploiting TAMs and tumor hypoxia have been proposed. 
Hypoxia-responsive polymeric micelles showed a superior therapeutic efficacy in mouse cancer 
models, following systemic administration. This effective anti-tumor activity in vivo, was due to the 
high selectivity and fast intracellular release of doxorubicin from the responsive nanoparticles, under 
low oxygen levels. Quantitative analysis showed a 4-fold increase in the accumulation of responsive 
hypoxia micelles in tumor tissues, compared to normal tissues, which resulted in a slower tumor 
growth [131]. Another approach to target tumor hypoxia was demonstrated by Wang et al and his 
team by developing micellar-based nanoparticles for the delivery of HIF-1α siRNA (EZN-2968). These 
nanoparticles showed specific gene knockdown both in vitro hypoxic mimicking cultures and in vivo 
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hypoxic tumor models for prostate cancer. HIF gene silencing inhibited cell migration and 
angiogenesis (reduction of VEGF levels) and increased the sensitivity of cancer cells to doxorubicin 
[132].  Recently, Quan et al reported the development of galactose-based thermosensitive nanogels 
as a theranostic system for hypoxic hepatocellular carcinoma [133]. The system was used to deliver 
iodoazomycin arabinofuranoside (IAZA), a radiosensitizer and a hypoxic imaging agent, to hypoxic 
hepatocellular carcinoma cells. IAZA-loaded nanogels showed a higher sensitization enhancement 
ratio, compared to IAZA alone. These results indicated that using nanogel particles could be a 
potentially useful approach to enhance the therapeutic efficacy of hypoxia radiosensitizers in tumor 
tissues. 
 
Fig 2. The hypoxic tumor environment and its role in oncogenesis . Deprivation of oxygen in the tumor core 
has been linked to tumor development and poor prognosis. Upregulation of HIF-1 has shown to enhance the 
expression of many cancer markers related to: (i) tumor angiogenesis, (ii) invasion and metastasis, (iii) 
metabolism shift and (iv) infiltration of M2 macrophages in the (v) hypoxic regions of tumors. The futile cycle 
created by the positive feedback of negative prognosis biomarkers in cancer are responsible for tumor survival 
and resistance to therapy.  
CCL17, Chemokine (C-C Motif) Ligand 17; CCL22, Chemokine (C-C Motif) Ligand 22; COX-2, 
cyclooxygenase-2; CXCL12, Chemokine (C-X-C Motif) Ligand 12; CXCR4, Chemokine (C-X-C Motif) 
Receptor 4; EGF, Epidermal growth factor; FGF2, fibroblast growth factor 2; HIF-1, Hypoxia inducible factor 
1; GLUT-1, Glucose transporter 1; MMP-7, Matrix metalloproteinase 7; MMP-9, Matrix metalloproteinase 9; 
MMP-12, Matrix metalloproteinase 12; PGK, Phosphoglycerate Kinase 1; TNF-α, Tumor necrosis factor 
alpha; VEGF, Vascular endothelial growth factor. 
 
Lately, trigger responsive drug delivery nanocarriers have been proposed to target the acidic 
tumor microenvironment that usually associated with hypoxia [11]. For example, Poon et al 
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developed pH-responsive sheddable nanoparticles, consisting of multiple layers, of which neutral 
layers shed in response to the acidic environment, exposing the charged nanoparticle surface to be 
easily taken up by tumor cells, while sparing healthy tissues [134]. In another study, Meng et al 
successfully developed pH-responsive nanovalves [135]. The porous mesoporous silica nanospheres 
were loaded with the drug and the pores were plugged with β-cyclodextrin. The interaction between 
the β-cyclodextrin and the stalk was dependent on the pH level, eventually facilitating diffusion of 
the drug from nanopores in the hypoxic tissues. The latter strategy was further improved by Dong et 
al who successfully developed pH-sensitive polymeric-coated porous silica nanoparticles, by using 
polyethylene imine (PEI) and PEI–PEG co-polymers. Both polymers improved the biodistribution of 
silica particles in vivo, where a superior tumor accumulation was observed with sterically stabilised 
nanoparticles [136]. More interestingly, photodynamic therapy (PDT) has been exploited to facilitate 
hypoxia generation, triggering drug release from hypoxia-responsive nanocarriers [137]. In this work, 
a ROS-generating and hypoxia-sensitive 2-nitroimidazole-grafted conjugated polymer (CP-NI) was 
synthesized, and doxorubicin (Dox) was successfully encapsulated within these polymeric 
nanoparticles. These multifunctional nanoparticles generate ROS upon near-infrared irradiation 
(NIR), leading to a rapid oxygen consumption within the tumor tissues, resulting in an efficient drug 
release from the nanocarriers. Such system showed promising in vitro and in vivo results, where 
mice treated with CP-NI-Dox in combination with NIR irradiation showed a complete tumor growth 
inhibition, with high levels of apoptosis as confirmed by TUNEL assay. Combining PDT with HAPs has 
been also considered as a promising approach to enhance the therapeutic efficacy of anti -cancer 
therapy, as discussed in section 2.2. 
The concept of using MACs as ‘trojan horses’ has proven to be an interesting approach in cancer 
therapy [138, 139]. Choi et al developed MACs loaded with gold nano-shell particles, which 
efficiently targeted the hypoxic regions of T47D breast cancer spheroids in vitro, and successfully 
slowed down the spheroid growth in combination with NIR [140]. A second study by Hirschberg et al 
showed the infiltration of gold–silica nanoshells-loaded MACs into glioma tumor spheroids [141]. 
Similarly, small gold nanorod-laden MACs (sAuNRs-laden MACs) with a smaller diameter of ~7 nm 
were able to infiltrate inaccessible tumor hypoxic regions, enhancing photothermal tumor ablation.  
The data showed that sAuNRs had higher cellular uptake (52.5%) and lower cytotoxicity in MACs, 
compared to other gold-based particles. RAW264.7 macrophages incubated with AuNRs and 
irradiated with 808 nm NIR laser, showed a significant cell death (higher ratio of cell apoptosis 
(32.6% ± 0.87) compared to the control group. Interestingly, these results were translated in vivo, 
where 95% tumor growth inhibition was observed in HepG2 tumor-bearing nude mice, with no 
visible recurrence [142]. Another study by Choi et al  reported the development of drug-loaded 
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MACs to treat cancer [143]. This novel therapeutic system was composed of mouse peritoneal MACs 
loaded with liposomal doxorubicin (macrophage-LP-Dox). Liposomal nanoparticles protected the 
MACs from the encapsulated doxorubicin in vitro, while delaying the tumor growth in animal 
models. These approaches highlight the potential use of MAC-based drug delivery systems to treat 
cancer. An Interesting work by Jiang et al using bone marrow derived MACs (BMDM) loaded with 
doxorubicin polymeric nanoparticles, demonstrated the deep penetration of doxorubicin into the 
tumor tissues, which was significantly higher in infrared irradiated tumors (IR) [144]. Such approach 
could be particularly suited to treating IR-induced recurrent tumors.  
Model simulations have suggested that, compared with conventional chemotherapy, MAC-based 
therapy preferentially targets tumor cells and diminishes the hypoxic cells in the tumor core [145]. In 
agreement with these simulations, Griffiths et al developed a successful approach using a gene-
dependent enzyme prodrug therapy (GDEPT), where MACs were transfected with adenoviral vectors 
that express cytochrome P450 [146]. The transfected MACs highly infiltrated tumor spheroids and 
enhanced the therapeutic activity of cyclophosphamide, a prodrug that induces tumor cell killing by 
the bystander effect. Treatment of spheroids with cyclophosphamide, after co-culture with 
transfected MACs, showed a significant reduction in spheroids volume. This approach became more 
promising after engineering adenoviral construct with a hypoxia-responsive promoter, where 
cytochrome P450 was only expressed in the hypoxic region of the tumor, hi ghlighting the specificity 
of the treatment. Subsequent exposure of the tumor spheroids to cyclophosphamide and MACs 
transfected with a hypoxia-responsive construct showed a specific inhibition of cell proliferation 
under hypoxic conditions. Furthermore, Lewis’ lab previously used MACs to efficiently deliver 
oncolytic viruses to hypoxic prostate cancer tissues in vivo. The engineered MACs were co-
transduced with a hypoxia-regulated E1A/B construct and an E1A-dependent oncolytic adenovirus, 
whose proliferation was restricted to prostate tumor cells using prostate-specific promoter elements 
from the TARP, PSA, and PMSA genes [138]. A single systemic injection of the oncolytic virus-loaded 
MACs resulted in a marked inhibition of tumor growth and reduction of pulmonary metastases. 
Furthermore, such approach enhanced the therapeutic efficacy of chemo- and radiotherapy in 
prostate cancer models [147].This data demonstrated the high potential of multifunctional 
nanotherapeutics which target tumor hypoxia and MACs.  
A second interesting approach was explored by Huang et al and co-workers [148, 149], who 
exploited the use of monocyte-mediated delivery of polymeric bubbles to potentiate re-oxygenation 
of tumor hypoxic areas, whilst enhancing the therapeutic efficacy of chemotherapy. In the first 
study, Huang et al presented an innovative strategy for overcoming the limited activity of 
photodynamic therapy (PDT) in hypoxic tumor tissues using bone marrow-derived monocytes as 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 29 
cellular vehicles for co-transport of oxygen and a light activated photosensitizer, chlorin e6 (Ce6). 
Superparamagnetic iron oxide nanoparticles (SPION)/Ce6/oxygen-loaded polymer bubbles were 
internalized into tumortropic monocytes. In this study, results showed that intratumoral 
administration of therapeutic monocytes exhibited a superior activity in inhibiting tumor growth in 
Tramp-C1 tumor-bearing mice upon the treatment with magnetic field and light laser. Histological 
examinations of the tumor sections confirmed the successful cellular transport of the therapeutic 
payloads to tumor hypoxia. This study demonstrated that oxygen/therapeutic co-delivery via 
tumortropic monocytes enhances tumor penetration, relieves tumor hypoxia after external 
hyperthermia trigger, and sensitizes cells to PDT [148]. In the second study [149], the same principle 
was applied for the co-delivery of polymeric bubbles and doxorubicin-loaded polymeric vesicles. 
Here, focused ultrasound was applied to trigger the release of drug-loaded vesicles from the 
monocytes within the hypoxic cores of tumors following cell infiltration. Once again, in vivo and ex 
vivo fluorescence imaging showed an appreciable accumulation of the doxorubicin-loaded 
monocytes at the tumor site.  With this, a high payload of drug was delivered deeper within the 
tumor mass, resulting in a pronounced cytotoxic effect. These studies clearly highlight the capability 
of MACs to deliver a wide range of therapeutics to deep tumour tissues, where the therapeutics 
efficacy was enhanced in combination with external triggers, such as laser i rradiation, hyperthermia 
or ultrasound, which facilitated drug release from the nanocarriers.   
Recently, manganese dioxide nanoparticles (MnO2 NPs) have been used to target TAMs and 
enhance tumor oxygenation [150]. In this study, Song et al developed novel nanoparticles that 
target TAMs in the hypoxic regions of the tumor. The high reactivity of MnO2 NPs toward hydrogen 
peroxide (H2O2) allowed the simultaneous production of O2 and regulation of pH in the hypoxic core. 
These nanoparticles were further modified with mannose and hyaluronic acid (HA) to promote M2 
targeting and TAMs repolarisation into M1 phenotype, respectively. The results showed higher 
association of the targeted particles to M2 mannose receptor in vitro, compared to untargeted 
particles (5-fold increase). Interestingly, targeted manganese dioxide particles showed a steady 
tumor uptake in vivo after intravenous injection and relatively low liver uptake. Flow cytometry 
assays, suggested the positively induced polarization of M2 to M1, with consequent production of 
high levels of H2O2 by these cells. The system improved the overall oxygenation and regulation of 
local hypoxic pH, in which the tumor showed 50.3% less tissue hypoxia, 49.3% decrease in the 
expression of HIF-1α, and 31.8% decrease in the expression of VEGF, 4 days after treatment. This 
study provided the opportunity to enhance chemotherapy response in 4T1 xenograft model by using 
combining Man-HA-MnO2 NPs and doxorubicin, where a significant reduction in xenograft tumor 
growth was observed. 
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Fig 3. Nanoparticle-based therapeutics targeting TAMs and hypoxia. Drug delivery systems (DDS) have 
shown great promises to inhibit the effect of TAMs and hypoxia on cancer development. The main mechanisms 
that have been developed so far using nanoparticles to targets tumor microenvironment are: 1) inhibiting 
monocyte maturation, leading to a reduced accumulation of pro-tumor immune cells (M2) at the tumor site; 2) 
depleting the tumor from M2 macrophages; 3) shifting the polarization of M2 macrophages (pro -tumor state) to 
an anti-tumor M1 state; 4) downregulating HIF-1with specific inhibitors and ligands; and 5) using macrophages 
as trojan horses to deliver DDS to the hypoxic regions of the tumor. 
CCL2, Chemokine (C-C Motif) Ligand 2; DDS, Drug delivery system; HIF-1, Hypoxia inducible factor 1; 
GLUT-1, Glucose transporter 1; IL-12, Interleukin 12; M-CSF, Macrophage colony stimulating factor; MMP-
7, Matrix metalloproteinase 7; MMP-9, Matrix metalloproteinase 9; TLR, Toll-like receptor; VEGF, Vascular 
endothelial growth factor 
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In summary, we have demonstrated here that targeting hypoxia and TAMs is, indeed, a promising 
therapeutic targets for cancer therapy. Their mechanisms of action are summarized in Fig. 3. 
Nanomedicine is a smart strategy to reassess old drugs and improve their pharmacokinetics and 
tumor targeting. Therefore, we believe that special considerations should be taken into account to 
design a combinatory treatment, capable of exerting synergistic effects in the tumor 
microenvironment. Several studies reviewed here took the advantages of oxygen 
generation/consumption to manipulate the hypoxia environment and to sensitize cancer cells to 
different treatment strategies. 
5. Clinical implications and future perspectives  
Hypoxia has become one of the most attractive targets in cancer [11]. Many small molecule 
inhibitors, HAPs and hypoxia-responsive nano-systems have shown a great promise in cancer 
therapy. However, hypoxia-targeted therapy has shown controversial results in mouse models and 
humans.  These high attrition rates of failure are attributed not only to the high complexity and 
redundancy of the tumor microenvironment, but also due to lack of veracity and fidelity in existing 
preclinical models and patient subsets. Therefore,  substantial efforts have been made to develop 
more reliable in vitro methods that can then be successfully translated to in vivo set-up and in 
patients [30]. For instance, the potential of these novel therapies must be validated at early stages, 
by fully establishing cell culture models that include comprehensive immunohistochemistry (IHC) 
staining, western blot analysis, and mRNA expression of direct and indirect pathways linked to 
hypoxia [27]. Limited molecular biological testing has been carried out due to the lack of well-
established robust biomarkers associated to hypoxia, and the nonexistence of in vitro models that 
can actively mimic the complex acidic, immune infiltrated tumor microenvironment, with 
heterogeneous expression of hypoxia-related genes. Nevertheless, biomimetic ‘organ/tumor-on-a-
chip’ tools have presented themselves as promising new in vitro tools, that could bring together the 
advantages of tumor spheroids [151], with the aid of microfluidic systems that can offer information 
on tumor heterogeneity, interstitial flow, cell binding and nanoparticle/drug accumulation [152]. 
Despite these challenges, efforts have been made to create more realistic pre-clinical and clinical 
models that are essential to fully understand, validate and successfully predict the outcome of these 
targeted therapies. More importantly, many open discussions on the matter have highlighted the 
importance of patient pre-selection for hypoxia and tumor microenvironment targeted therapies 
[30]. Previous clinical set-ups have failed to show relevant positive outcomes, due to inadequate 
patients standardization. Many patient subsets did not show a relevant expression of HIF-1. Also, a 
good percentage of the patients showed mixtures of well-oxygenated and hypoxic tumors, or poorly 
established immune microenvironment that conferred reduced benefit of the applied treatment. 
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Clearly, there is still much to be done to perform adequate evaluation of these treatments, but 
recent efforts to establish xenograft models that constitutively represent HIF-1 expression 
encourage future studies and reliable clinical translation [143, 153]. Furthermore, the new interest 
to combine HAPs with drugs that are known to lowering tumor oxygen levels and potentiating 
tumour hypoxia, such as some VEGF inhibitors and photosensitizers, could enhance the therapeutic 
efficacy of the combinatory treatments, and overcome the oxygen tumor heterogeneity.   
Similar to hypoxia, tumors have been known for their heterogeneity in blood supply, which 
results occasionally in inevitable disappointment once translated to clinical trials. This tumor 
heterogeneity makes it difficult to predict drug efficacy in tumor models, or to extrapolate the 
clinical efficacy of drugs in humans based on in vivo mice models. In support of this, Danhier et al has 
recently highlighted the need to reassess the concept of nanomedicine in a clinical aspect, mainly 
regarding its benefits when exploiting the enhanced permeation and retention (EPR) effect [154]. 
Danhier argues that although the EPR is probably one of the most cited and important concepts in 
nanomedicine, it is a heterogeneous process, highly variable between tumors and within the same 
tumor mass, and not the main attribute for the high success of novel nano-therapies. Nevertheless, 
as aforementioned, we highlight the importance of using more relevant models that can translate 
the results obtained in murine models to cancer patients. For example, patient-derived tumor 
explant (PDX) models, can alternatively provide an accurate model of morphology, complexity , and 
heterogeneity of human tumors [155, 156]. More promisingly, extensive work has been published in 
the last two decades to overcome the EPR hurdles, using mild hyperthermia and sonoporation to 
improve drug accumulation and penetration within the tumor mass [157-160]. We believe that the 
future prospects and success of tumor microenvironment targeted therapies rely on establishing 
strong validated models that truly represents tumors in cancer patients. Additionally, the use of 
combinatorial synergistic chemotherapeutics, that nanomedicine could offer, may provide a means 
to overcome tumor complexity, providing a more favourable realistic outcome.  
Our review suggests that drug combination and time of therapy are the key factors that should 
be taken into consideration when designing combinatorial therapies for hypoxia, especially when 
translated to clinical trials. Previous pre-clinical studies have provided evidence that angiogenesis 
inhibition through TAM targeting can indeed inhibit tumor growth [161, 162]. Most importantly, 
TAM depletion which potentiates tumor hypoxia could be overcome if correctly combined with 
angiogenesis and/or hypoxia-targeted therapies [161, 162]. Although targeting TAMs and hypoxia 
individually has shown a great promise, we believe that developing combinatorial therapies 
exploiting both targets may ensure strong synergistic effects, and render solid tumors more 
susceptible to conventional cancer therapies. Such strategies can provide a sophisticated approach 
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to target multiple signaling pathways in tumorigenesis, and overcome off-target effects from 
positive loop feedbacks generated between TAMs, hypoxia and the tumor microenvironment. These 
studies provide evidence that simultaneously targeting TAMs and hypoxia is an interesting novel 
approach to exploit in cancer therapy.  
Despite the apparent controversy and disappointing results discussed above, researchers must 
not forget the high number of newly approved drug delivery systems and ongoing clinical trials 
[152]. Therefore, we support aforementioned opinions that targeting the tumor microenvironment 
must be revised, and translation to clinic must be supported by adequate pre-clinical evaluation 
alongside standardized patients selection. Researchers need to focus not only on showing 
sophisticated nanomedicine with enhanced efficacy, but they should discover new techniques that 
can identify new tumor microenvironment biomarkers that could offer a personalised medicine for 
cancer patients. This can lead to the development of new targeted systems, and also aid in 
identifying tumors that will respond better to certain drug regimen. Efforts are in place to take 
nanomedicine closer to clinical translation by producing more reliable and positive treatment 
outcomes.  
6. Conclusions  
Significant progress has been made on deciphering the role of hypoxia and MACs infiltration in 
tumor malignancy. In the present work, we give an in-depth review on the active role of the tumor 
microenvironment in cancer survival and the development of drug resistance. TAMs have been 
considered as potential therapeutic targets for cancer therapy, since they are strongly linked to 
hypoxia and cancer progression. MACs have been envisioned as ‘trojan horses’, given their enhanced 
extravasation in hypoxic tumor cores. These features offer a great opportunity to design highly 
selective and sophisticated drug delivery systems that simultaneously target TAMs and tumor 
hypoxia. We believe that adopting this new approach is anticipated to overcome drug resistance and 
enhance the efficacy of chemotherapy in advanced solid and metastatic tumors . Finally, with 
validated tumor models and standardized patient pre-selection, and targeting hypoxia and TAMs, 
combinatory nanomedicine can become a more reliable therapeutic tool with more favourable 
clinical outcomes in the future. 
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Figure captions 
Fig 1. Main hallmarks of cancer. The cancer niche is a complex network of endothelial, stromal and malignant 
cells, comprised of evolutionary genomic features that enhance survival and thrive tumor cells to uncontrolled 
proliferation and metastasis.  This enriched tumor microenvironment supports a shifted metabolism in cells, 
which allows a quick preadaptation and survival under nutrient and oxygen deprivation (hypoxia) which lead to 
therapeutic resistance.  
Fig 2. The hypoxic tumor environment and its role in oncogenesis . Deprivation of oxygen in the tumor core 
has been linked to tumor development and poor prognosis. Upregulation of HIF-1 has shown to enhance the 
expression of many cancer markers related to: (i) tumor angiogenesis, (ii) invasion and metasta sis, (iii) 
metabolism shift and (iv) infiltration of M2 macrophages in the (v) hypoxic regions of tumors. The futile cycle 
created by the positive feedback of negative prognosis biomarkers in cancer are responsible for tumor survival 
and resistance to therapy.  
CCL17, Chemokine (C-C Motif) Ligand 17; CCL22, Chemokine (C-C Motif) Ligand 22; COX-2, 
cyclooxygenase-2; CXCL12, Chemokine (C-X-C Motif) Ligand 12; CXCR4, Chemokine (C-X-C Motif) 
Receptor 4; EGF, Epidermal growth factor; FGF2, fibroblast growth factor 2; HIF-1, Hypoxia inducible factor 
1; GLUT-1, Glucose transporter 1; MMP-7, Matrix metalloproteinase 7; MMP-9, Matrix metalloproteinase 9; 
MMP-12, Matrix metalloproteinase 12; PGK, Phosphoglycerate Kinase 1; TNF-α, Tumor necrosis factor 
alpha; VEGF, Vascular endothelial growth factor 
Fig 3. Nanoparticle-based therapeutics targeting TAMs and hypoxia. Drug delivery systems (DDS) have 
shown great promises to inhibit the effect of TAMs and hypoxia on cancer development. The main mechanisms 
that have been developed so far using nanoparticles to targets tumor microenvironment are: 1) inhibiting 
monocyte maturation, leading to a reduced accumulation of pro-tumor immune cells (M2) at the tumor site; 2) 
depleting the tumor from M2 macrophages; 3) shifting the polarization of M2 macrophages (pro -tumor state) to 
an anti-tumor M1 state; 4) downregulating HIF-1with specific inhibitors and ligands; and 5) using macrophages 
as trojan horses to deliver DDS to the hypoxic regions of the tumor.  
CCL2, Chemokine (C-C Motif) Ligand 2; DDS, Drug delivery system; HIF-1, Hypoxia inducible factor 1; 
GLUT-1, Glucose transporter 1; IL-12, Interleukin 12; M-CSF, Macrophage colony stimulating factor; MMP-
7, Matrix metalloproteinase 7; MMP-9, Matrix metalloproteinase 9; TLR, Toll-like receptor; VEGF, Vascular 
endothelial growth factor  
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